Real-World Outcomes in <i>FLT3</i>-ITD Mutated Acute Myeloid Leukemia: Impact of NPM1 Mutations and Allogeneic Transplantation in a Retrospective Unicentric Cohort.

J Clin Med · 2025 · PMC12294857 · PMID 40725802

Europe PMC DOI

hedged sentences

0.0860

closest p · 1.7× alpha

0.0860

boldest claim

The sentences

showed a trendp = 0.086so close (0.05 < p ≤ 0.1)

In a landmark analysis restricted to patients transplanted in CR1, those who had received midostaurin-based induction showed a trend toward improved OS compared to those treated with standard induction (median OS not reached vs. 11.5 months; 95% CI, 0.5–25.0; p = 0.086).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

However, these improvements did not reach statistical significance in our cohort.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Real-World Outcomes in &lt;i&gt;FLT3&lt;/i&gt;-ITD Mutated Acute Myeloid Leukemia: Impact of NPM1 Mutations and Allogeneic Transplantation in a Retrospective Unicentric Cohort.

The sentences

Real-World Outcomes in <i>FLT3</i>-ITD Mutated Acute Myeloid Leukemia: Impact of NPM1 Mutations and Allogeneic Transplantation in a Retrospective Unicentric Cohort.